Broadening its efforts to defuse outrage over skyrocketing prices, the pharmaceutical industry’s lobbying association has started an advertising campaign urging insurers to share with customers more of the benefits of rebates they’ve negotiated.
A sexual harassment scandal involving host Bill O’Reilly has prompted major advertisers such as Eli Lilly and Co. and several automakers to drop out. Indianapolis-based Angie’s List is among those sticking with the show.
Dave Ricks joined Lilly in 1996 and most recently served as president of Lilly Bio-Medicines. He took over as president and CEO on Jan. 1.
Taltz, which hit the market last year, is taking on an armful of older treatments, including creams, lotions, pills and injectables, such as Amgen’s Enbrel and AbbVie’s Humira.
Share of Eli Lilly and Co. and numerous other drug industry stocks fell Tuesday morning after the president sent a tweet promising to lower medicine costs for American people.
Getting elected mayor requires fine-tuned political instincts. Sometimes, those instincts say it’s time to leave a high-level job at the biggest company in town.
Alzheimer’s disease is rewriting the rules of drug discovery, with companies like Eli Lilly and others abandoning caution to keep pursuing an elusive hypothesis because the potential payoff is so great.
Eli Lilly and Co. said Bart Peterson, who served two terms as Indianapolis mayor, was stepping down as senior vice president "to pursue personal business interests" and expand his community volunteer commitments.
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
The Indianapolis-based drugmaker has offered many of its research and development employees a compensation package if they leave the company.
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
For drugmakers, including Indianapolis-based Eli Lilly and Co., a meeting Tuesday with President Donald Trump was a dose of happy pills.
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
The Indianapolis-based drugmaker got a revenue boost from a host of new medications but also saw sales fall sharply for some older products.
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
Alex Azar, president of Lilly USA LLC since 2012, is leaving the company just as his unit is about to lose a huge swath of sales personnel. The drugmaker announced a series of changes Thursday under new CEO David Ricks.
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
Eli Lilly and Co. shares rose sharply Thursday morning after the company presented a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer’s treatment in testing.
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
